|Assessment Status||Rapid Review Complete|
|Indication||For the treatment of moderate-to-severe atopic dermatitis in adults aged 18 years and older who are candidates for systemic therapy.|
|Rapid review commissioned||16/09/2019|
|Rapid review completed||11/10/2019|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that argipressin acetate (Embesin®) not be considered for reimbursement at the submitted price*.|
The HSE has approved reimbursement following confidential price negotiations, March 2020.
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.